Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis healing:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose typically 40 mg orally twice daily, may be increased to a maximum of 240 mg daily in divided doses.
## Pediatric Dosing
* **Erosive esophagitis healing (ages 5 to 16 years):** 20 mg orally once daily for up to 4 weeks.
* **Erosive esophagitis healing (ages 5 to 16 years, if not healed):** An additional 4 weeks of treatment with 20 mg orally once daily may be considered.
* **Higher doses (up to 40 mg daily) may be considered for GERD in pediatric patients based on clinical judgment and therapeutic response.**
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, flatulence, and dizziness.
## Key Drug Interactions
* **Rilpivirine:** Concomitant use is contraindicated due to risk of virologic failure and potential for resistance.
* **Drugs dependent on gastric pH for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, ampicillin esters, and erlotinib.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, though clinical significance is debated).
## Monitoring
* Monitor for symptom improvement.
* Long-term use of PPIs may be associated with increased risk of bone fractures (hip, wrist, spine), *Clostridioides difficile*-associated diarrhea, vitamin B12 deficiency, and hypomagnesemia. Consider periodic assessment of magnesium levels in patients on long-term therapy.
## Clinical Pearls
* Administer 30 to 60 minutes before a meal.
* Pantoprazole oral suspension should not be mixed with other medications.
***
*This information is intended for clinical use and does not replace full prescribing information. Always consult the most current official drug monograph for complete details.*
